- Home
- IEX vs MDGL Comparison
IEX vs MDGL Comparison
Compare IEX & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEX | MDGL |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 12.5B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | IEX | MDGL |
|---|---|---|
| Price | $195.57 | $495.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $201.40 | ★ $597.54 |
| AVG Volume (30 Days) | ★ 584.7K | 330.7K |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $3,421,300,000.00 | $740,640,000.00 |
| Revenue This Year | $6.31 | $435.42 |
| Revenue Next Year | $2.91 | $54.59 |
| P/E Ratio | $30.83 | ★ N/A |
| Revenue Growth | 7.09 | ★ 864.21 |
| 52 Week Low | $153.36 | $265.00 |
| 52 Week High | $226.05 | $615.00 |
Technical Indicators
Market Signals| Indicator | IEX | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 39.19 |
| Support Level | $193.79 | $465.98 |
| Resistance Level | $200.32 | $502.36 |
| Average True Range (ATR) | 3.93 | 20.75 |
| MACD | 0.22 | -2.41 |
| Stochastic Oscillator | 80.90 | 30.57 |
Price Performance
Historical ComparisonAbout IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.